Impact of Pharmaceutical Interviews on the Medication Adherence of Epileptic Patients
NCT04876820 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51
Last updated 2025-05-29
Summary
Many studies have reported a disparity in medication adherence among epileptic patients. In this population, Medication Possession Ratio (MPR) is an index of medication adherence. MPR is defined as the ratio of the number of days of treatment delivered to the number of days in the period of interest.
No-adherents patients are defined by a MPR of less than 80% , in whom an increase in seizures and the rate of hospitalization can be observed. A pharmacist-led intervention and medication information to epileptic patients could improve patient medication adherence to antiepileptic drugs, and possibly decrease the frequency of seizures, hospitalizations and the health costs generated by these hospitalizations. This intervention could also improve patient knowledge about their medications.
The aim of this study is to evaluate the effectiveness of a pharmacist-led intervention on medication adherence of epileptic patients with the MPR. Secondary objectives include the comparison of medication adherence with health insurance score, the evaluation of patients knowledges about their medications, community pharmacists' satisfaction about community hospital network, the comparison of the seizure free patient rate and the comparison of the rate of patient in whom seizure have decreased by 50%
Conditions
Interventions
- OTHER
-
Pharmacist intervention
In the intervention arm, the patient meets with the pharmacist. Pharmaceutical intervention (H1) about anti-epileptic drugs prescribed will be done: information on when to take the medication, what to do if you forget to take it or vomit, and an explanation of adverse events. The aim is to improve medication adherence and patient knowledge. A report will be sent to the community pharmacist. An assessment of medication adherence to antiepileptic drug by MPR at H1 3 months and 6 months (phone call to community pharmacist) will be done. The health insurance score will also be done. An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at H1 in pre- post interview -, 3 and 6 months (phone call to patient) will be done. An assessment of pharmacists' satisfaction about community hospital network by a satisfaction questionnaire will be done.
- OTHER
-
Standard of care
An assessment of medication adherence to antiepileptic drug by MPR at the inclusion then 3 months and 6 months later will be done by a phone call to the community pharmacist. An assessment of patient knowledge by a self-made knowledge questionnaire (10 items) at the inclusion then 3 and 6 months later will be done by a phone call to the patient. The health insurance score will be also done during this call.
Sponsors & Collaborators
-
University Hospital, Lille
lead OTHER
Principal Investigators
-
Philippe DERAMBURE, MD,PhD · University Hospital, Lille
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-01
- Primary Completion
- 2024-10-01
- Completion
- 2024-10-01
Countries
- France
Study Locations
More Related Trials
-
Medication Adherence in Individuals With Epilepsy
NCT01566500 ·Status: COMPLETED
-
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
NCT05772429 ·Status: ACTIVE_NOT_RECRUITING
-
Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs
NCT02556320 ·Status: COMPLETED ·Phase: NA
-
Precision Medicine in the Treatment of Epilepsy
NCT05450822 ·Status: RECRUITING
-
The Effect of Anti-epileptic Drugs on Mitochondrial Activity
NCT01218321 ·Status: COMPLETED
-
Adherence to Pharmacological Antiepileptic Treatment in Adolescence
NCT05825807 ·Status: UNKNOWN
-
Evaluation Of A Mobile Messaging Service In Improving Adherence Of Anti-Seizure Medications
NCT05321641 ·Status: UNKNOWN ·Phase: NA
-
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
NCT00351611 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Incidence of Psychiatric Disorders As a Function of First-line Antiepileptic Drug Prescribing Practices: Use of Assurance Maladie Databases
NCT06829693 ·Status: NOT_YET_RECRUITING
-
NYU Epilepsy Self-Management Study
NCT07087821 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
NCT06769659 ·Status: RECRUITING ·Phase: PHASE2
-
Probiotic in Treatment of Adult Patients With Drug-resistant Epilepsy
NCT05160350 ·Status: COMPLETED ·Phase: PHASE4
-
Study The Knowledge and Attitude Towards Epilepsy Among Relatives of People With Epilepsy and Their Impact on The Patient's Quality of Life
NCT05671575 ·Status: UNKNOWN
-
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
NCT00280059 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring
NCT02679846 ·Status: COMPLETED ·Phase: NA
-
Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents
NCT05126914 ·Status: RECRUITING
-
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
NCT00210522 ·Status: COMPLETED ·Phase: PHASE2
-
Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY
NCT03419000 ·Status: COMPLETED ·Phase: NA
-
Intermittent Fasting in Refractory Epilepsy
NCT02311023 ·Status: TERMINATED ·Phase: PHASE2
-
Drug Resistant Epilepsy: Clinical and Genetic Study
NCT04166305 ·Status: UNKNOWN
-
An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy
NCT01682681 ·Status: COMPLETED
-
The Efficacy and Safety of Minocycline in the Treatment of Drug-resistant Epilepsy in NORSE Patients
NCT05958069 ·Status: UNKNOWN ·Phase: NA
-
LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures
NCT00144872 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy
NCT04714996 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy
NCT06354868 ·Status: NOT_YET_RECRUITING